Sitaxentan

Also known as: Sitaxsentan, TBC-11251, IPI-1040, N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(2-methyl-4,5-methylenedioxyphenyl)acetyl]thiophene-3-sulfonamide, N-(4-Chloro-3-methylisoxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide, Sitax

Sitaxentan (CAS 184036-34-8) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C18H15ClN2O6S2 and a molecular weight of 454.90500 g/mol. Key properties include a boiling point of 600.4ºC at 760 mmHg, a density of 1.6g/cm3 and a flash point of 316.9ºC. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 184036-34-8
Jingsj CID: J-1957150-7
Molecular Formula: C₁₈H₁₅ClN₂O₆S₂
Molecular Weight: 454.90500 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Boiling Point	600.4ºC at 760 mmHg
Density	1.6g/cm3
Flash Point	316.9ºC
Exact Mass	454.00600
PSA	144.35000
LogP	5.11500
Vapor Pressure	2.25E-14mmHg at 25°C
Refractive Index	1.687
Storage Conditions	2-8℃

Activity & Biological Data

Additional Information	[1]. Chin M, Levy RD, Yoshida EM, Byrne MF.Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.Can Respir J. 2012 Jan-Feb;19(1):e1-2. [2]. Sandoval J, et al. STRIDE-4 investigators.Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.Pulm Pharmacol Ther. 2012 Feb;25(1):33-9. Epub 2011 Nov 2. [3]. Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.Vasc Health Risk Manag. 2011;7:119-24. Epub 2011 Mar 2. [4]. Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6. [5]. Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr. 2011 Apr;123(7-8):248-52. Epub 2011 Mar 31.

Additional Information

[1]. Chin M, Levy RD, Yoshida EM, Byrne MF.Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.Can Respir J. 2012 Jan-Feb;19(1):e1-2. [2]. Sandoval J, et al. STRIDE-4 investigators.Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.Pulm Pharmacol Ther. 2012 Feb;25(1):33-9. Epub 2011 Nov 2. [3]. Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.Vasc Health Risk Manag. 2011;7:119-24. Epub 2011 Mar 2. [4]. Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6. [5]. Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr. 2011 Apr;123(7-8):248-52. Epub 2011 Mar 31.

Frequently Asked Questions

What is the CAS number of Sitaxentan?

The CAS number of Sitaxentan is 184036-34-8.

What are the molecular formula and molecular weight of Sitaxentan?

Sitaxentan has molecular formula C18H15ClN2O6S2 and molecular weight 454.90500 g/mol.

What are the upstream and downstream products of Sitaxentan?

For Sitaxentan, Upstream Products: 3-[(4-chloro-3-methyl-1,2-oxazol-5-yl)sulfamoyl]-N-methoxy-N-methylthiophene-2-carboxamide, 5-(Chloromethyl)-6-methyl-1,3-benzodioxole, 5-(Chloromethyl)-1,3-benzodioxole.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Sitaxentan (CAS 184036-34-8)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1957150-7 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.